



Announcement Summary

**Entity name**

TELIX PHARMACEUTICALS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Wednesday July 09, 2025

**The +securities to be quoted are:**

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

**Total number of +securities to be quoted**

ASX +security code	Security description	Number of +securities to be quoted	Issue date
TLX	ORDINARY FULLY PAID	16,445	26/06/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

**1.2 Registered number type**

ACN

**Registration number**

616620369

**1.3 ASX issuer code**

TLX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

9/7/2025

For personal use only



Part 2 - Type of Issue

---

**2.1 The +securities to be quoted are:**

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

**2.2 The +class of +securities to be quoted is:**

Additional +securities in a class that is already quoted on ASX ("existing class")

For personal use only



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**Existing +securities converting into additional +securities in an existing class**

**FROM (Existing Class)**

**ASX +security code and description**

TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37

**TO (Existing Class)**

**ASX +security code and description**

TLX : ORDINARY FULLY PAID

**Please state the number of options that were exercised or other +convertible securities that were converted**

12,595

**The first date the options were exercised or other +convertible securities were converted**

23/6/2025

**The last date the options were exercised or other +convertible securities were converted**

26/6/2025

**Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?**

No

**The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:**

An issue of new +securities

**The underlying +securities being received by the holder are:**

Intended to be, but are not yet, quoted by ASX

**Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?**

Yes

**Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate?**

No

**Issue date**

26/6/2025

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

For personal use only



## Issue details

**Number of +securities to be quoted**

12,595

**Are the +securities being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid? What is the issue price per +security?**

AUD - Australian Dollar

AUD 5.37000000

**Any other information the entity wishes to provide about the +securities to be quoted****Existing +securities converting into additional +securities in an existing class****FROM (Existing Class)****ASX +security code and description**

TLXAO : SHARE APPRECIATION RIGHTS

**TO (Existing Class)****ASX +security code and description**

TLX : ORDINARY FULLY PAID

**Please state the number of options that were exercised or other +convertible securities that were converted**

5,058

**The first date the options were exercised or other +convertible securities were converted**

23/6/2025

**The last date the options were exercised or other +convertible securities were converted**

26/6/2025

**Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?**

No

**The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:**

An issue of new +securities

**The underlying +securities being received by the holder are:**

Intended to be, but are not yet, quoted by ASX

**Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?**

Yes

**Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate?**

No

**Issue date**

26/6/2025

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes



Issue details

---

**Number of +securities to be quoted**

3,850

**Are the +securities being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

Shares issued from exercise of vested 2022 PSARs under Telix EIP valued in accordance with the independent Black Scholes methodology disclosed in the AGM Notice of Meeting held 18 May 2022.

**Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted**

6.150000

**Any other information the entity wishes to provide about the +securities to be quoted**

Refer <https://ir.telixpharma.com/reports> for AGM documentation and also Telix 2024 Remuneration report within the 2024 Annual Report

---

For personal use only



## Part 4 - Issued capital following quotation

**Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLX : ORDINARY FULLY PAID	338,399,059

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,440,000
TLXAO : SHARE APPRECIATION RIGHTS	15,700,490
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	242,397
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	10,561
TLXAV : DEFERRED SHARE RIGHTS US 2024	10,342
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	2,881,250
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	289,225
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000